|
Oct 9
|
AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
|
|
Sep 30
|
AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
|
|
Sep 27
|
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
|
|
Aug 20
|
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
|
|
Aug 16
|
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
|
Jul 29
|
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
|
|
Jul 24
|
AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
|
|
Jun 10
|
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
|
|
May 20
|
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
|
|
Mar 15
|
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
|
|
Jan 24
|
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
|
|
Jan 22
|
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
|
|
Jan 10
|
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
|
|
Dec 29
|
Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are Invalid
|
|
Nov 28
|
AIM ImmunoTech Provides Update Regarding Annual Meeting
|
|
Nov 28
|
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
|
|
Nov 15
|
AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
|
|
Nov 14
|
AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer
|
|
Nov 9
|
AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast
|
|
Nov 8
|
AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer
|